Hims & Hers Health (HIMS) Stock Overview
Operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
HIMS Community Fair Values
Create NarrativeSee what 919 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Hims & Hers Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$27.41 |
| 52 Week High | US$70.43 |
| 52 Week Low | US$13.74 |
| Beta | 2.31 |
| 1 Month Change | 43.21% |
| 3 Month Change | 7.32% |
| 1 Year Change | -34.55% |
| 3 Year Change | 131.31% |
| 5 Year Change | 165.60% |
| Change since IPO | 179.69% |
Recent News & Updates
HIMS: Novo Partnership And GLP 1 Pivot Will Support Future Profitability
Analysts have reset their price target framework for Hims & Hers Health to $35.00, incorporating more tempered revenue growth assumptions, a slightly higher discount rate, an improved profit margin outlook, and a lower future P/E multiple informed by recent research citing both the renewed Novo Nordisk partnership and evolving GLP-1 and legal risk views. Analyst Commentary Street research on Hims & Hers Health has shifted meaningfully in recent months, with several firms revising price targets and ratings after the renewed Novo Nordisk partnership, changes in GLP-1 offerings, and evolving views on legal and regulatory risk.
Hims & Hers Paves the Path to $1 Billion Quarterly Revenue in end of 2026
Recent deal and acquisition news have shed more light on the path to growth.Recent updates
HIMS: Novo Partnership And GLP 1 Pivot Will Support Future Profitability
Analysts have reset their price target framework for Hims & Hers Health to $35.00, incorporating more tempered revenue growth assumptions, a slightly higher discount rate, an improved profit margin outlook, and a lower future P/E multiple informed by recent research citing both the renewed Novo Nordisk partnership and evolving GLP-1 and legal risk views. Analyst Commentary Street research on Hims & Hers Health has shifted meaningfully in recent months, with several firms revising price targets and ratings after the renewed Novo Nordisk partnership, changes in GLP-1 offerings, and evolving views on legal and regulatory risk.Hims & Hers Paves the Path to $1 Billion Quarterly Revenue in end of 2026
Recent deal and acquisition news have shed more light on the path to growth.
HIMS: Renewed GLP 1 Partnership Will Face Lingering Regulatory And Execution Risks
The analyst price target for Hims & Hers Health increases slightly to $24.31 from $24.15 as analysts factor in easing peptide restrictions, reduced litigation risk and the renewed Novo Nordisk partnership, along with updated assumptions for future P/E and profitability. Analyst Commentary Recent research on Hims & Hers Health clusters around two themes: renewed optimism tied to the Novo Nordisk partnership and easing peptide restrictions, and lingering concerns around GLP-1 execution, earnings quality, and legal or regulatory risk.Hims & Hers: Bargain EBITDA Multiples As GLP-1 Drama Passes
Apr 14HIMS: Renewed GLP 1 Partnership Will Shape Future Upside Potential
The analyst price target for Hims & Hers Health has moved slightly higher to about $24, as analysts factor in updated views on GLP-1 partnerships, reduced litigation risk, and mixed reactions to recent guidance updates. Analyst Commentary Recent research views on Hims & Hers Health show a wide range of opinions, with some firms lifting targets and ratings on the back of the Novo Nordisk partnership and GLP-1 potential, while others remain cautious after prior guidance updates, litigation concerns, and questions around compounded GLP-1 products.HIMS: Novo Partnership And Menopause Expansion Will Shape Balanced Future Upside
The updated analyst price target for Hims & Hers Health shifts from about $44 to around $24 as analysts factor in slightly lower assumptions for revenue growth and profit margins, along with a more conservative future P/E multiple, even though there have been recent target raises tied to reduced legal risk and new GLP-1 partnership opportunities. Analyst Commentary Recent Street research around Hims & Hers Health clusters around two themes: the renewed agreement with Novo Nordisk on branded GLP-1s and a reset of expectations after the Q4 report and 2026 guidance.Review of status after Q4 2025 results
A lot has happened since the last update. This status check is explaining where is Hims and how to reach long term goals.
FY2025
Updated with most recent annual report.
HIMS: GLP-1 Regulatory And Legal Pressures Will Limit Future Share Upside
The Analyst Price Target for Hims & Hers Health has been trimmed from $13.00 to $12.50 as analysts factor in recent target cuts tied to regulatory questions around compounded GLP-1s, softer profit expectations, and mixed post earnings commentary across the Street. Analyst Commentary Recent research updates point to a clear reset in expectations for Hims & Hers Health, with multiple firms cutting price targets following the latest Q4 report, guidance, and growing regulatory questions around compounded GLP-1 offerings.HIMS: Legal And Regulatory Setbacks Will Restrain Future Share Returns
The updated analyst price target for Hims & Hers Health has moved from $25.00 to $13.00, reflecting a broad reset from recent firm cuts as analysts weigh legal risk and adjust their P/E and growth assumptions. Analyst Commentary Recent Street research has largely moved in the same direction, with multiple bearish analysts trimming their targets on Hims & Hers Health by double digit dollar amounts.The Price Is Right For Hims & Hers Health, Inc. (NYSE:HIMS) Even After Diving 46%
Feb 11
HIMS: Lab Testing Expansion Will Support Weight Loss And Future Profitability
Analysts trimmed their price target on Hims & Hers Health by about US$10.64, citing updated views on fair value, revenue growth, profit margins, and future P/E expectations following recent research. Analyst Commentary Recent research updates on Hims & Hers Health reflect a reset in fair value assumptions, including a lower price target of about US$25 from one firm, along with a closer look at revenue growth trajectories, margin profiles, and future P/E expectations.Updated perspective to the company future
A different way to look at the future of Hims and Hers - the subscriber countHims & Hers Health - Valuation
🩺 Business Overview Key Metrics Total: -3/17 +1 ✅ Projected Operating Margin: 13.90% +1 ✅ Projected 5-Year Revenue CAGR: 13.87% -2 ❌❌ Last 5-Year ROIC: -7.80% -2 ❌❌ Estimated Cost of Capital: 7.76% (greater than ROIC) -1 ❌ Last 5-Year Shares Outstanding CAGR: +2.65% +2 ✅✅ Projected 5-Year EPS CAGR: 23.29% +0 ⚠️ Projected 5-Year Dividend CAGR: N/A +2 ✅✅ Estimated Debt Rating: Aaa -2 ❌❌ Morningstar Moat: None -2 ❌❌ Morningstar Uncertainty: Very High Hims & Hers Health is a high growth company, being currently on a rapid expansion of its business. This has some advantages like the projected stellar growth of both revenue and EPS but it will also normally represent the dillution of shares to support it and the negative ROIC (lower than the cost of capital) that it should be regularized during the next couple of years.HIMS: GLP-1 Pricing Shifts Will Support Weight Loss And Labs Expansion
Analysts have trimmed their fair value estimate for Hims & Hers Health from US$82.55 to US$74.54, citing lower assumed revenue growth, slightly softer profit margins, and reduced future P/E expectations as competition and GLP-1 pricing changes from TrumpRx, Eli Lilly, and Novo Nordisk reshape the weight loss market. Analyst Commentary Recent research has focused on how GLP-1 pricing changes and the upcoming TrumpRx platform could affect Hims & Hers Health's weight loss offering, particularly its compounded GLP-1 products.Revised analysis by adding bear scenario to the weight loss.
Market is currently pricing heavy challenges for the weight loss business of Hims and Hers. This is due to: 1) End of Semaglutide shortage, 2) Deal broken with Novo, 3) Warning letter from FDA Therefore added scenario to Hims losing growth in weight loss.
Revised calculations
More accurate calculations. Made text of the analysis more clear and simple, for easy reading.HIMS: GLP Pricing And Margin Pressure Will Constrain Future Share Returns
Narrative Update: Hims & Hers Health Analysts have trimmed their blended price target on Hims & Hers Health by about $7 per share, to roughly $59, reflecting cautious views on GLP-1 pricing pressure and margin potential, even as they acknowledge broader growth opportunities such as the new menopause offering and international expansion. Analyst Commentary Recent research on Hims & Hers Health highlights a mix of product expansion and pricing risk, with attention centered on GLP-1 weight loss offerings, the new menopause service, and how these shape the company’s long term margin profile.Hims & Hers Health (NYSE:HIMS) Seems To Use Debt Rather Sparingly
Jan 03HIMS: GLP Pricing Pressure Will Challenge Future Margin Expansion
Analysts have trimmed their fair value estimate for Hims & Hers Health from $28.00 to $25.00 per share, reflecting expectations for slower revenue growth, lower margins, a slightly higher discount rate, and increased competitive pressure on GLP-1 pricing that partially offsets the companys broader treatment expansion. Analyst Commentary Recent Street research reflects a more cautious stance on Hims & Hers Health, with several bearish analysts flagging execution and competitive risks that could weigh on the companys valuation.HIMS: Menopause Expansion Will Drive Future Upside Despite Weight Loss Pricing Headwinds
Analysts have trimmed their average price target on Hims & Hers Health from approximately $46.00 to about $44.36 per share, reflecting expectations for stronger top line growth but slightly lower long term margins as GLP 1 pricing dynamics, competitive pressures and new service investments temper profitability and valuation multiples. Analyst Commentary Bullish analysts highlight that Hims and Hers continues to post solid growth trends despite near term headwinds.HIMS: Expanding Women's Health and Lab Testing Will Unlock New Market Opportunities
Analysts have trimmed their price target for Hims & Hers Health from $46.67 to $46.00 per share. This reflects increased uncertainty around GLP-1 pricing dynamics and competitive pressures in the direct-to-consumer healthcare market.The Price Is Right For Hims & Hers Health, Inc. (NYSE:HIMS) Even After Diving 29%
Nov 18HIMS: Expanding Women's Health Services Will Drive Broader Market Reach
The average analyst price target for Hims & Hers Health has been modestly lowered by approximately $0.75 to $46.67 per share, as analysts trim revenue growth expectations. They also point to intensifying competition and pressure on pricing in the GLP-1 market.Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 33% Share Price Bounce
Sep 27Telehealth And Hormonal Health Will Transform Global Markets
Hims & Hers Health faces increased regulatory and legal risks, slowing customer growth, and business momentum concerns, prompting analysts to lower their price target from $49.45 to $47.42. Analyst Commentary Increased regulatory headwinds following new FDA reforms for direct-to-consumer advertising, making customer acquisition and marketing more challenging across digital and broadcast platforms.What You Can Learn From Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S After Its 26% Share Price Crash
Jul 22📈 HIMS' Asymmetric Opportunity, JIN’s Overlooked Strengths, and PROX's Possible Re-Rating
May 21
Hims: The Platform Powering Personalised Healthcare
Platform Play, Not a Pill Company: Hims is building the infrastructure for personalised, direct-to-consumer healthcare across diagnostics, treatment, and prevention, similar to what Amazon did for retHims & Hers Health's (NYSE:HIMS) Performance Is Even Better Than Its Earnings Suggest
May 13Shareholder Returns
| HIMS | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -6.7% | 2.6% | 0.9% |
| 1Y | -34.6% | -3.6% | 28.2% |
Return vs Industry: HIMS underperformed the US Healthcare industry which returned -3.6% over the past year.
Return vs Market: HIMS underperformed the US Market which returned 28.2% over the past year.
Price Volatility
| HIMS volatility | |
|---|---|
| HIMS Average Weekly Movement | 17.8% |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: HIMS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: HIMS's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 2,442 | Andrew Dudum | www.hims.com |
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers.
Hims & Hers Health, Inc. Fundamentals Summary
| HIMS fundamental statistics | |
|---|---|
| Market cap | US$6.25b |
| Earnings (TTM) | US$128.37m |
| Revenue (TTM) | US$2.35b |
48.7x
P/E Ratio2.7x
P/S RatioIs HIMS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HIMS income statement (TTM) | |
|---|---|
| Revenue | US$2.35b |
| Cost of Revenue | US$614.26m |
| Gross Profit | US$1.73b |
| Other Expenses | US$1.61b |
| Earnings | US$128.37m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 11, 2026
| Earnings per share (EPS) | 0.56 |
| Gross Margin | 73.84% |
| Net Profit Margin | 5.47% |
| Debt/Equity Ratio | 179.8% |
How did HIMS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/04 21:09 |
| End of Day Share Price | 2026/05/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hims & Hers Health, Inc. is covered by 22 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vikram Kesavabhotla | Baird |
| Glen Santangelo | Barclays |
| Allen Lutz | BofA Global Research |